Visit Date: March 5, 2026 | Review Date: March 19, 2026
From: Psychiatric MD Collaborator | To: Stacy Pascarella, APRN
Collaborative Agreement: Psychiatry MD-APRN Practice
Overall Assessment: REASONABLE AND APPROVED WITH ENHANCEMENTS
The clinical decision-making demonstrates comprehensive medication management, appropriate risk mitigation, and strong patient-centered care. The current course is reasonable and approvable with specific recommendations to optimize outcomes, particularly regarding stimulant formulation, mood stabilization, and liver risk stratification.
Issue Enhancement Matrix
Issue
Current Approach
Recommended Enhancement
🔴 Lamotrigine dosing
100mg daily
Titrate to 200mg for optimal bipolar depression coverage; current dose subtherapeutic
Venlafaxine SNRI effects
187.5mg daily
Risk of mood elevation in bipolar II; add lithium/valproate if cycling emerges, or consider bupropion substitution for less manic risk
Nightmare disorder
Prazosin 2mg continued
Trial gabapentin 300-600mg at bedtime or topiramate 25-50mg if prazosin ineffective; consider polysomnography if trauma-content
TD monitoring
AIMS score 7, stable
Quarterly AIMS given history; VMAT2 inhibitor (deutetrabenazine or valbenazine) if functionally impairing
🔴 Liver risk stratification
Naltrexone + alcohol history + abnormal LFTs
Urgent LFT completion before travel; FibroScan if available; if elevated, hold naltrexone; consider acamprosate alternative (renal excretion)
Specific Recommendations for Further Improvement
1. Mood Stabilization Optimization
Lamotrigine titration: Increase to 150mg × 2 weeks, then 200mg if tolerated
Target 200mg for bipolar depression efficacy (evidence-based dose)
Venlafaxine risk mitigation: SNRIs carry higher manic switch risk than SSRIs in bipolar disorder
Alternative: Split dosing IR 20mg AM + 10mg early afternoon if XR poorly tolerated
Sleep protection: Ensure 8+ hours between last stimulant dose and bedtime
Doxepin 10mg provides adequate antagonism for sleep onset
3. Nightmare Disorder Reassessment
Prazosin efficacy uncertain; consider 2-week trial discontinuation with nightmare diary
If nightmares trauma-content or PTSD features: EMDR referral prior to travel
Pharmacologic alternatives: Gabapentin 300-600mg at bedtime or topiramate 25-50mg (mood stabilizing, weight-neutral, nightmare reduction)
[RAG] Topiramate evidence: Nightmare reduction in PTSD; weight-neutral profile beneficial for comorbid metabolic concerns
4. Tardive Dyskinesia Management
Current: AIMS 7, minimal severity, stable since Geodon discontinuation
Quarterly AIMS monitoring required with documented informed consent
If progressive or distressing: VMAT2 inhibitor trial
Options: Deutetrabenazine 6mg BID or valbenazine 40mg daily
[RAG] VMAT2 inhibitors: FDA-approved for TD; deutetrabenazine QD dosing improves adherence; valbenazine effective for moderate-severe TD
🔴 5. Alcohol Use Disorder and Hepatic Risk (CRITICAL)
URGENT: Complete pending LFTs before India departure
If elevated (>3x ULN): Hold naltrexone immediately
Initiate acamprosate 666mg TID (non-hepatic metabolism) as alternative
Alternative: Disulfiram if abstinence goal and no contraindications
GI/hepatology referral coordination for fibrosis staging
Consider FibroScan if available for non-invasive fibrosis assessment
Omega-3 supplementation: 2-4g EPA+DHA daily for hepatic steatosis and mood support
[RAG] Acamprosate: Renal excretion, no hepatic metabolism, safe in liver disease; disulfiram requires absolute alcohol abstinence; omega-3 evidence for depression and emerging for NAFLD
6. Binge Eating Disorder Formalization
PHQ-9 Item 5 elevated (3/3); body image rumination prominent
Add Binge Eating Scale (BES) for severity quantification
Consider lisdexamfetamine 50-70mg if ADHD and BED co-treatment indicated (FDA-approved for BED; prodrug with lower misuse potential)
Topiramate alternative if stimulant contraindicated (weight loss, binge reduction; monitor cognitive side effects)
[RAG] Lisdexamfetamine: FDA-approved for moderate-severe BED; single daily dosing; prodrug design reduces diversion risk compared to immediate-release stimulants
7. Travel Preparation
Controlled substance documentation: Travel letter for Adderall
Verify India customs requirements (stimulants may be restricted)
Medication supply: 90-day fills obtained; ensure backup pharmacy identification in India
Emergency plan: Identify psychiatric resources in destination city; telehealth continuity plan
Strengths of Current Course
✅ Comprehensive medication reconciliation with extensive prior trial documentation
✅ Appropriate naltrexone initiation with liver risk counseling
✅ Proactive travel planning with early refill coordination
✅ Strong therapeutic alliance; patient engaged and motivated
✅ Recognition of afternoon IR crash and formulation change indicated
✅ TD monitoring with stable AIMS documentation
Follow-up Parameters
Timeline
Action
Responsible
🔴 Immediate (pre-travel)
Complete LFTs; review results; hold/adjust naltrexone if elevated
Quarterly AIMS; biannual LFTs if stable; annual FibroScan if hepatic steatosis
APRN/MD
Final Determination
Current Course: REASONABLE AND APPROVED
Priority Enhancements:
Lamotrigine titration to 200mg
Urgent LFT completion with naltrexone risk stratification
Adderall XR conversion approved
Quarterly TD monitoring formalized
Prognosis: Favorable given strong engagement, medication adherence, and active self-monitoring; hepatic risk and mood stabilization are primary monitoring targets.